Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LYPLAL1 antisense RNA 1 (head to head) (LYPLAL1-DT, also known as LYPLAL1-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand adjacent to the protein-coding gene LYPLAL1 on chromosome 1q41[1][2][8]. It is classified as a divergent transcript and acts as an antisense lncRNA, but it does not encode a protein[1][7]. While its precise functions remain incompletely defined, LYPLAL1-DT may regulate the cell-type-specific expression of the adjacent LYPLAL1 gene in cis[3]. There are currently no known roles for this transcript as a therapeutic target, no approved drugs targeting it, and no established links to specific diseases or biomarker usage[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LYPLAL1 antisense RNA 1 (head to head) (LYPLAL1-DT).